SM
ARCT icon

Sabby Management’s Arcturus Therapeutics ARCT Stock Holding History

Sabby Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-80
Closed -$117K – 266
2016
Q4 		$117K Hold
80
– – 0.01% 265
2016
Q3 		$138K Buy
80
+22
+38% +$711 0.01% 284
2016
Q2 		$184K Buy
+58
New +$1.83K 0.01% 251
2014
Q4 		– Sell
-523
Closed -$5.65M – 247
2014
Q3 		$5.65M Buy
523
+495
+1,768% +$64.5K 0.22% 60
2014
Q2 		$344K Buy
+28
New +$3.38K 0.01% 204

Other funds holding ARCT

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
DI
DFPG Investments Sandy, Utah $1.28B AUM 27.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Sabby Management's ARCT Position: Q4 2019 in Review

Sabby Management sold out of Arcturus Therapeutics (ARCT) in Q4 2019, closing a stake of 124,843 shares — an estimated $1.28M sold.

Sabby Management first reported a position in ARCT in Q4 2013 and held it in 7 quarters. The position peaked at $2.28M in Q4 2013. 50 funds tracked by Wall St. Rank hold ARCT as of Q4 2019.

  • Sabby Management reported no remaining Arcturus Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Sabby Management sold 124,843 Arcturus Therapeutics shares in Q4 2019, an estimated $1.28M.
  • Sabby Management first reported a position in Arcturus Therapeutics in Q4 2013 and held it in 7 quarters.
  • Sabby Management's Arcturus Therapeutics position peaked at $2.28M in Q4 2013.
  • 50 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2019.

Based on Sabby Management's 13F filing for Q4 2019, filed 14 Feb 2020.